The treatment of aggressive prolactinomas with everolimus.

Lin, Andrew L; Geer, Eliza B; Lala, Nupur; Page-Wilson, Gabrielle; Magge, Rajiv; Young, Robert J; Tabar, Viviane

Lin, Andrew L; Geer, Eliza B; Lala, Nupur; Page-Wilson, Gabrielle; Magge, Rajiv; Young, Robert J; Tabar, Viviane.

Afiliación

Lin AL; Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lina1@mskcc.org.
Geer EB; Department of Neurology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA. lina1@mskcc.org.
Lala N; Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA. lina1@mskcc.org.
Page-Wilson G; Department of Neurology, Weill Cornell Medical College, New York, NY, USA. lina1@mskcc.org.
Magge R; Department of Neurosurgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Young RJ; Multidisciplinary Pituitary and Skull Base Tumor Center, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Tabar V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Pituitary ; 26(4): 474-481, 2023 Aug.

Article en En | MEDLINE | ID: mdl-37428396

Asunto(s)

Neoplasias Hipofisarias; Prolactinoma; Humanos; Prolactinoma/patología; Everolimus/uso terapéutico; Temozolomida/uso terapéutico; Neoplasias Hipofisarias/patología; Agonistas de Dopamina

Palabras clave

Aggressive pituitary adenoma; Pituitary carcinoma; Prolactinoma; Targeted therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Hipofisarias / Prolactinoma Tipo de estudio: Prognostic_studies Límite: Humans Idioma: En Revista: Pituitary Asunto de la revista: ENDOCRINOLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google